Revisiting dose-finding of monoclonal antibodies in migraine

[1]  D. Hay,et al.  CGRP physiology, pharmacology, and therapeutic targets: Migraine and beyond. , 2022, Physiological reviews.

[2]  M. Weatherall,et al.  Long‐term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis , 2022, Headache.

[3]  S. Sacco,et al.  Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study , 2022, The Journal of Headache and Pain.

[4]  M. Ferrari,et al.  CGRP-mediated trigeminovascular reactivity in migraine patients treated with erenumab , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[5]  P. Goadsby,et al.  Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions , 2022, The Lancet Neurology.

[6]  R. Ruscheweyh,et al.  Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study , 2021, Cephalalgia : an international journal of headache.

[7]  A. Maassenvandenbrink,et al.  Metabolic Aspects of Migraine: Association With Obesity and Diabetes Mellitus , 2021, Frontiers in Neurology.

[8]  E. Ludwig,et al.  Relationship of the Calcitonin Gene‐Related Peptide Monoclonal Antibody Galcanezumab Pharmacokinetics and Capsaicin‐Induced Dermal Blood Flow in Healthy Subjects , 2021, Clinical pharmacology in drug development.

[9]  A. Maassenvandenbrink,et al.  Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications. , 2021, Maturitas.

[10]  E. Loder,et al.  Real-world effectiveness and tolerability of erenumab: A retrospective cohort study , 2020, Cephalalgia : an international journal of headache.

[11]  K. Cahill,et al.  Oral Candidiasis in a Migraine Patient Taking Erenumab and Galcanezumab: a Case Report , 2020, SN Comprehensive Clinical Medicine.

[12]  W. Kielbasa,et al.  Population Pharmacokinetics of Galcanezumab, an Anti‐CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine , 2019, Journal of clinical pharmacology.

[13]  S. Sacco,et al.  CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? , 2019, The Journal of Headache and Pain.

[14]  Edgar Bautista,et al.  Phase I, Randomized, Double‐blind, Placebo‐controlled, Single‐dose, and Multiple‐dose Studies of Erenumab in Healthy Subjects and Patients With Migraine , 2018, Clinical pharmacology and therapeutics.

[15]  D. Grayzel,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers , 2017, Front. Pharmacol..

[16]  E. Lesaffre,et al.  The influence of migraine and female hormones on capsaicin-induced dermal blood flow , 2017, Cephalalgia : an international journal of headache.

[17]  T. Vu,et al.  Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects , 2017, Pharmaceutical Research.

[18]  T. Vu,et al.  Pharmacokinetic-Pharmacodynamic Relationship of Erenumab (AMG 334) and Capsaicin-Induced Dermal Blood Flow in Healthy and Migraine Subjects , 2017, Pharmaceutical Research.

[19]  J. Hoon,et al.  Development of anti‐migraine therapeutics using the capsaicin‐induced dermal blood flow model , 2015, British journal of clinical pharmacology.

[20]  S. Kushner,et al.  Reduced trigeminovascular cyclicity in patients with menstrually related migraine , 2015, Neurology.

[21]  K. Ibrahimi,et al.  Development of an experimental model to study trigeminal nerve-mediated vasodilation on the human forehead , 2014, Cephalalgia : an international journal of headache.

[22]  R. Lipton,et al.  Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS) , 2012, The Journal of Headache and Pain.

[23]  B. Van der Schueren,et al.  Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging. , 2007, British journal of clinical pharmacology.

[24]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..